These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31494719)

  • 41. Patient Cohort Identification on Time Series Data Using the OMOP Common Data Model.
    Maier C; Kapsner LA; Mate S; Prokosch HU; Kraus S
    Appl Clin Inform; 2021 Jan; 12(1):57-64. PubMed ID: 33506478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Data model harmonization for the All Of Us Research Program: Transforming i2b2 data into the OMOP common data model.
    Klann JG; Joss MAH; Embree K; Murphy SN
    PLoS One; 2019; 14(2):e0212463. PubMed ID: 30779778
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data.
    Zebenholzer K; Gall W; Wöber C
    J Headache Pain; 2018 May; 19(1):34. PubMed ID: 29777424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transforming and evaluating electronic health record disease phenotyping algorithms using the OMOP common data model: a case study in heart failure.
    Papez V; Moinat M; Payralbe S; Asselbergs FW; Lumbers RT; Hemingway H; Dobson R; Denaxas S
    JAMIA Open; 2021 Jul; 4(3):ooab001. PubMed ID: 34514354
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Creating a Common Data Model for Comparative Effectiveness with the Observational Medical Outcomes Partnership.
    FitzHenry F; Resnic FS; Robbins SL; Denton J; Nookala L; Meeker D; Ohno-Machado L; Matheny ME
    Appl Clin Inform; 2015; 6(3):536-47. PubMed ID: 26448797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Semantic Transformation Methodology for the Secondary Use of Observational Healthcare Data in Postmarketing Safety Studies.
    Pacaci A; Gonul S; Sinaci AA; Yuksel M; Laleci Erturkmen GB
    Front Pharmacol; 2018; 9():435. PubMed ID: 29760661
    [No Abstract]   [Full Text] [Related]  

  • 47. Secondary Use of Claims Data from the Austrian Health Insurance System with i2b2: A Pilot Study.
    Endel F; Duftschmid G
    Stud Health Technol Inform; 2016; 223():245-52. PubMed ID: 27139410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of a common data model for active safety surveillance research.
    Overhage JM; Ryan PB; Reich CG; Hartzema AG; Stang PE
    J Am Med Inform Assoc; 2012; 19(1):54-60. PubMed ID: 22037893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis.
    Smith MY; Sabidó-Espin M; Trochanov A; Samuelson M; Guedes S; Corvino FA; Richy FF
    J Manag Care Spec Pharm; 2015 Aug; 21(8):650-60. PubMed ID: 26233537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extract, transform, load framework for the conversion of health databases to OMOP.
    Quiroz JC; Chard T; Sa Z; Ritchie A; Jorm L; Gallego B
    PLoS One; 2022; 17(4):e0266911. PubMed ID: 35404974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model.
    Matcho A; Ryan P; Fife D; Reich C
    Drug Saf; 2014 Nov; 37(11):945-59. PubMed ID: 25187016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.
    Schuemie MJ; Gini R; Coloma PM; Straatman H; Herings RM; Pedersen L; Innocenti F; Mazzaglia G; Picelli G; van der Lei J; Sturkenboom MC
    Drug Saf; 2013 Oct; 36 Suppl 1():S159-69. PubMed ID: 24166232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the cohort selection performance of Australian Medicines Terminology to Anatomical Therapeutic Chemical mappings.
    Guo GN; Jonnagaddala J; Farshid S; Huser V; Reich C; Liaw ST
    J Am Med Inform Assoc; 2019 Nov; 26(11):1237-1246. PubMed ID: 31545380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Towards Implementation of OMOP in a German University Hospital Consortium.
    Maier C; Lang L; Storf H; Vormstein P; Bieber R; Bernarding J; Herrmann T; Haverkamp C; Horki P; Laufer J; Berger F; Höning G; Fritsch HW; Schüttler J; Ganslandt T; Prokosch HU; Sedlmayr M
    Appl Clin Inform; 2018 Jan; 9(1):54-61. PubMed ID: 29365340
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transfer of Clinical Drug Data to a Research Infrastructure on OMOP - A FAIR Concept.
    Reinecke I; Zoch M; Wilhelm M; Sedlmayr M; Bathelt F
    Stud Health Technol Inform; 2021 Nov; 287():63-67. PubMed ID: 34795082
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and Validation of the Radiology Common Data Model (R-CDM) for the International Standardization of Medical Imaging Data.
    Park C; You SC; Jeon H; Jeong CW; Choi JW; Park RW
    Yonsei Med J; 2022 Jan; 63(Suppl):S74-S83. PubMed ID: 35040608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Translating the Observational Medical Outcomes Partnership - Common Data Model (OMOP-CDM) Electronic Health Records to an OWL Ontology.
    Jean-Baptiste L; Mouazer A; Sedki K; Tsopra R
    Stud Health Technol Inform; 2022 Jun; 290():76-80. PubMed ID: 35672974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data.
    Ammann EM; Kalsekar I; Yoo A; Johnston SS
    Pharmacoepidemiol Drug Saf; 2018 Oct; 27(10):1092-1100. PubMed ID: 30003617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterizing the Anticancer Treatment Trajectory and Pattern in Patients Receiving Chemotherapy for Cancer Using Harmonized Observational Databases: Retrospective Study.
    Jeon H; You SC; Kang SY; Seo SI; Warner JL; Belenkaya R; Park RW
    JMIR Med Inform; 2021 Apr; 9(4):e25035. PubMed ID: 33720842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utilizing Medicare claims data for real‐time drug safety evaluations:is it feasible?
    Hartzema AG; Racoosin JA; MaCurdy TE; Gibbs JM; Kelman JA
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):684-8. PubMed ID: 21847800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.